SCHEMBL13246348

SCHEMBL13246348

CCOC(=O)N1CCC(COc2ccc(C)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 3/20 0.60
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
PKM P14618 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TSHR P16473 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HRH2 P25021 1/20 0.48
HRH1 P35367 1/20 0.48
NOS3 P29474 1/20 0.48
NOS1 P29475 1/20 0.48
NOS2 P35228 1/20 0.48
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13450952 0.86 GRIN2B (0.71) GRIN2BSMN1; SMN2MEN1KMT2A
SCHEMBL12834985 0.85 GPR119 (0.58) GRIN2BPKMKMT2AKDM4E
SCHEMBL2456940 0.83 HRH2 (0.51) GRIN2BMAPTLMNAGAASMN1; SMN2
SCHEMBL18842715 0.82 GPR119 (0.57) KMT2A
SCHEMBL10385453 0.80 ALDH1A1 (0.58) GRIN2BLMNAGAASMN1; SMN2PKM
SCHEMBL14067300 0.79 MAPT (0.51) MAPTGAAL3MBTL1
SCHEMBL7035676 0.79 GRIN2B (0.58) GRIN2BSMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL7392069 0.78 CHEK2 (0.55) MAPTLMNAPKMKMT2AKDM4E
SCHEMBL21009699 0.77 MAOA (0.53)
SCHEMBL14389737 0.77 CYP1A2 (0.60) GRIN2BMAPTGAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372860-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2013-02-12 US disclosed
EP-2298304-A2 Carboline derivatives useful in the treatment of cancer PTC Therapeutics, Inc. (US) 2011-03-23 EP disclosed
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS PTC THERAPEUTICS, INC. 2010-07-15 US disclosed
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. 2010-06-24 US disclosed
US-7601840-B2 Carboline derivatives useful in the inhibition of angiogenesis PTC THERAPEUTICS, INC. (US) 2009-10-13 US disclosed
WO-2008127714-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES PTC THERAPEUTICS, INC. (US) 2008-10-23 WO disclosed
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration PCT THERAPEUTICS, INC. (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158858-A1 ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES RNMT, VEGFA, VHL GRIN2B 3315/4885MAPT 3101/4885LMNA 3138/4885
US-20070281962-A2 Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration VEGFA, FLT4, MIF GRIN2B 4311/4885MAPT 2854/4885LMNA 3199/4885
US-20100179132-A1 CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS VEGFA, FLT4, PGF GRIN2B 4540/4885MAPT 4804/4885LMNA 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.